OncoTricks

Clots in pregnancy and antiphospholipid syndrome, Oct 23, 2026

A clot in pregnancy

A woman at 14 weeks has a left leg deep vein thrombosis and a pulmonary embolism. She is on enoxaparin. The referral asks hematology to "evaluate for thrombophilia".

If you remember one thingHeparin until delivery and at least six weeks after; she never takes estrogen again.

Concepts first

WHAT YOU NEED BEFORE THE NUMBERS Why pregnancy clots more fibrinogen, factor VIII,von Willebrand factor less protein S slower flow in the legs vessel injury at delivery built to stop bleeding at birth; the price is venous clots When the risk peaks pregnancy and 3 months after: about 4 times the risk after delivery the yearly rate is about 5 times the rate during pregnancy (Heit 2005); most of the risk falls in the first 6 weeks (Bates 2018) Does it cross the placenta? heparins (enoxaparin,unfractionated): no warfarin: yes apixaban, rivaroxaban:probably; fetal effectsunknown, so not used heparin for the whole pregnancy (Bates 2012; Bates 2018) WHICH THROMBOPHILIA TEST CAN YOU READ NOW? Readable now factor V Leiden, prothrombin gene (DNA) anticardiolipin, anti-beta-2-glycoprotein I If low, repeat 6 to 12 weeks after birth protein S and C, antithrombin, lupus anticoagulant

A low protein S in pregnancy is physiology, not a diagnosis.Free protein S falls in normal pregnancy, antithrombin falls on heparin, and all three proteins can be consumed by the acute clot. A normal result still excludes deficiency; only a low one is repeated 6 to 12 weeks after delivery, off anticoagulation. Anticardiolipin and anti-beta-2-glycoprotein I are not affected by heparin, but a positive at the time of the clot needs a repeat at 12 weeks or more. None of this changes the dose in this pregnancy; it decides whether anticoagulation stops after it (Middeldorp 2023).

From diagnosis to six weeks after birth

THERAPEUTIC ANTICOAGULATION, ONE PREGNANCY enoxaparin, full dose delivery 6 weeks or more diagnosis 36 to 37 weeks stop, if 3 months done 1 mg/kg twice daily, or 1.5 mg/kg once daily (label) no routine anti-Xa level plan the birth with obstetrics and anesthesia last full dose 24 h before a spinal or epidural after it: low dose at 12 h; full dose at 24 h, never with the catheter in heparin or warfarin, both fine with breastfeeding; no apixaban or rivaroxaban Once or twice daily both acceptable (Bates 2018); 6 weeks after birth, 3 months total (Bates 2012) neuraxial: Kopp 2025, Leffert 2018; no neuraxial: 4 to 6 h after vaginal, 6 to 12 h after cesarean

anti-Xa a blood level of heparin activity: not routine for a clot in pregnancy (Bates 2018); required with a mechanical heart valve (twice-daily dosing, peak and trough targets set with cardiology); consider in antithrombin deficiency, kidney failure, or weight under 50 or over 120 kg · neuraxial spinal or epidural anesthesia · postpartum after delivery

If the clot is in the arm or neck in the first trimester, ask how she got pregnant.Most pregnancy leg clots are on the left: 88% in a systematic review of 6 studies (Chan 2010). After ovarian hyperstimulation for assisted reproduction, clots can appear in the upper body, sometimes weeks after it resolved (Chan 2008). Also ask about a central line and thoracic outlet compression.

Suspected clot in a pregnant woman: ultrasound first, and include the iliac veins.Leg symptoms: compression ultrasound with the iliac veins; if negative and suspicion persists, repeat it or image the pelvis. Suspected embolism: ultrasound of the legs if they hurt; otherwise the pregnancy-adapted YEARS algorithm, the only validated way to use the D-dimer in pregnancy (van der Pol 2019), then imaging. The radiation from a lung scan or a CT angiogram is far below the dose that harms a fetus.

Warfarin and the pregnant woman

WHERE WARFARIN HURTS THE FETUS 0612203040 weeks switch to heparin before here embryopathy flat nose, stippled bone ends brain abnormalities and fetal bleeding warfarin reaches the fetus at any age; the fetal liver cannot make enough clotting factors, so delivery on warfarin is dangerous (Bates 2012) Warfarin through pregnancy embryopathy in 6.4% of live births; heparin by week 6 removed it (Chan 2000) Mechanical valves are different at 5 mg or less, fewer fetal problems (Vitale 1999); cardiology decides

The woman on warfarin who wants a pregnancy needs a plan before she conceives.Switch to heparin before trying, or test for pregnancy often and switch as soon as it is confirmed, ideally before week 6 (Tektonidou 2019). After delivery warfarin is back on the table: it was not detected in the milk of 13 mothers or in the blood of 7 breastfed infants, and clotting tests were normal in the 3 infants tested (Orme 1977). Start it with full-dose heparin, overlapping at least 5 days and until the INR is 2 or more for 24 hours (Bates 2012).

Decide in clinic

1. Clot during this pregnancy?
yes
Full-dose heparin to delivery, then at least 6 weeks, and at least 3 months totalEnoxaparin twice daily or once daily (Bates 2018). Thrombophilia results do not change the dose now. Persistent antiphospholipid antibodies would mean thrombotic antiphospholipid syndrome: warfarin preferred over direct oral anticoagulants, and the duration after a pregnancy-provoked clot is individualized, longer with a high-risk antibody profile (Tektonidou 2019).
then
2. Delivery approaching?
36 weeks
Write the plan with obstetrics and anesthesiaPlanned induction; cesarean only for obstetric reasons. Last full dose 24 hours before neuraxial anesthesia. Tell her: no injection once contractions, broken waters or bleeding start. Clot in the last month, or preterm birth likely: switch to intravenous unfractionated heparin, stopped 4 to 6 hours before neuraxial with a normal partial thromboplastin time (ACOG 2018). After a spinal or epidural: prophylactic dose no sooner than 12 hours; full dose no sooner than 24 hours, and never with the catheter in place, at least 4 hours after removal (Kopp 2025; Leffert 2018). A retrievable vena cava filter only if a fresh clot must go untreated at delivery.
then
3. Breastfeeding?
yes
Heparin or warfarinNot apixaban, rivaroxaban or dabigatran (Bates 2018). Without a spinal or epidural, obstetrics restarts heparin 4 to 6 hours after a vaginal birth or 6 to 12 hours after a cesarean, often at prophylactic dose first (ACOG 2018).
and for life
4. No estrogen-containing contraception, and heparin in every future pregnancyNo combined pill, patch or ring. An intrauterine device (levonorgestrel or copper) or the progestin-only pill is fine; the levonorgestrel device also treats heavy bleeding on anticoagulation. Next pregnancy: fixed prophylactic dose (enoxaparin 40 mg daily) from early pregnancy until 6 weeks after delivery; a weight-adjusted intermediate dose was no better, 2% vs 3% recurrence (Bistervels 2022, Highlow trial). Women on long-term anticoagulation switch to full-dose heparin instead.
Sources

Retrieved from PubMed, read on Oct 23, 2026.

  1. Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018. doi:10.1182/bloodadvances.2018024802
  2. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins, Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy. Obstet Gynecol 2018. doi:10.1097/AOG.0000000000002706
  3. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012. doi:10.1378/chest.11-2300
  4. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005. doi:10.7326/0003-4819-143-10-200511150-00006
  5. Kopp SL, Vandermeulen E, McBane RD, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fifth edition). Reg Anesth Pain Med 2025. doi:10.1136/rapm-2024-105766
  6. Leffert L, Butwick A, Carvalho B, et al. The Society for Obstetric Anesthesia and Perinatology consensus statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants. Anesth Analg 2018. doi:10.1213/ANE.0000000000002530
  7. Chan WS, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ 2010. doi:10.1503/cmaj.091692
  8. Chan WS, Dixon ME. The "ART" of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res 2008. doi:10.1016/j.thromres.2007.05.023
  9. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000. doi:10.1001/archinte.160.2.191
  10. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv 2023. doi:10.1182/bloodadvances.2023010177
  11. van der Pol LM, Tromeur C, Bistervels IM, et al. Pregnancy-adapted YEARS algorithm for diagnosis of suspected pulmonary embolism. N Engl J Med 2019. doi:10.1056/NEJMoa1813865
  12. Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999. doi:10.1016/S0735-1097(99)00044-3
  13. Orme ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed their infants? Br Med J 1977. doi:10.1136/bmj.1.6076.1564
  14. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019. doi:10.1136/annrheumdis-2019-215213
  15. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020. doi:10.1002/art.41191
  16. Bistervels IM, Buchmüller A, Wiegers HMG, et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet 2022. doi:10.1016/S0140-6736(22)02128-6

Antiphospholipid syndrome: the 2023 criteria, point by point

The 2006 criteria (called Sapporo, revised in Sydney) let three unexplained miscarriages before 10 weeks, plus an antibody positive twice 12 weeks apart, make the syndrome (Miyakis 2006). In 2023 the American College of Rheumatology and the European Alliance of Associations for Rheumatology (ACR and EULAR) rebuilt the criteria with weighted points. They are written for research, and they changed who counts.

If you remember one thingEarly miscarriages no longer make the syndrome: they score 1 of the 3 clinical points needed.

Concepts first

WHAT THE WORDS MEAN The syndrome a clot or a pregnancy complication, plus an antibody that persists the antibody targets proteins bound to phospholipid, mostly beta-2-glycoprotein I The three tests BY CLOTTING TIME lupus anticoagulant BY ELISA (ANTIBODY LEVEL) anticardiolipin IgG, IgM anti-beta-2-glycoprotein I IgG, IgM IgG, IgM: antibody classes Classify vs diagnose criteria pick patients for studies: built to be specific, not sensitive a patient who misses them can still be treated; the decision is clinical

The score

ENTRY: one positive antibody test within 3 years of the clinical event then add points; count only the highest item in each domain CLINICAL DOMAINS Venous clotwith a high-risk clot profile1without one3high risk: 1 major (surgery, cancer, bed rest)or 2 minor (pregnancy, obesity, estrogen) Arterial clotwith high cardiovascular risk2without it4high risk: 1 high-level or3 moderate cardiovascular factors Small vesselssuspected (skin, kidney, lung)2established (biopsy, imaging)5 Heart valve and plateletsvalve thickening2valve vegetation4platelets 20 to 130 thousand2 Pregnancy 3 or more consecutive losses before 16 weeks (before 10, or 10 to 15 weeks)1 fetal death 16 to 33 weeks, no severe preeclampsia or placental insufficiency1 severe preeclampsia OR severe placental insufficiency before 34 weeks3 severe preeclampsia AND severe placental insufficiency before 34 weeks4 LABORATORY DOMAINS (PERSISTENT: POSITIVE TWICE, AT LEAST 12 WEEKS APART) Lupus anticoagulantpositive once1persistent5 The two ELISAs, each persistentIgM only, moderate or high1IgG moderate4IgG high, one of the two5IgG high, both antibodies7 Classified: 3 or more clinical points AND 3 or more laboratory points

ELISA enzyme-linked immunosorbent assay, a test that measures the antibody level · IgG, IgM antibody classes; IgG carries more weight · preeclampsia with severe features new high blood pressure in pregnancy with organ damage (kidney, liver, platelets, brain) · placental insufficiency a placenta that fails to feed the fetus: a small baby, abnormal umbilical artery flow, low amniotic fluid · skin livedo racemosa, a broken, irregular, persistent violet net (the regular, reversible livedo reticularis does not count) · points from Barbhaiya 2023

The new criteria trade sensitivity for specificity.In the validation cohort, specificity rose from 86% to 99% and sensitivity fell from 99% to 84% compared with the 2006 Sapporo criteria (Barbhaiya 2023). An event counts only if there is no equally or more likely explanation: a miscarriage of a fetus with a chromosome abnormality does not score.

What no longer counts

Off the scoreAntibody levels below 40 units. IgA antibodies. Anti-phosphatidylserine/prothrombin, a newer antibody test. An ELISA positive once and never repeated. A lupus anticoagulant drawn on warfarin, heparin or a direct oral anticoagulant, unless reviewed by an expert coagulation laboratory (Barbhaiya 2023). The cutoffs are for ELISA units; chemiluminescence assays report units that are not interchangeable.
Still the strongest signalA persistent lupus anticoagulant, or high IgG in both ELISAs. Triple positivity, all three tests persistently positive, is the core of the high-risk antibody profile (Tektonidou 2019). A single lupus anticoagulant scores only 1, and is read with caution during anticoagulation, an acute clot or pregnancy.

Order it right.All three tests together: lupus anticoagulant, and IgG and IgM for both anticardiolipin and anti-beta-2-glycoprotein I. Draw the lupus anticoagulant off anticoagulation, or tell the lab what she is on. Repeat any positive at 12 weeks or more. Count points only when both results are back.

Sources

Retrieved from PubMed, read on Oct 23, 2026.

  1. Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 2023. doi:10.1002/art.42624
  2. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019. doi:10.1136/annrheumdis-2019-215213
  3. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006. doi:10.1111/j.1538-7836.2006.01753.x

Antiphospholipid syndrome: warfarin, aspirin, pregnancy loss

Three women with persistent antiphospholipid antibodies: one with a clot on warfarin who wants a baby, one with a fetal death at 24 weeks and no clot, one with a positive test on a routine panel and nothing else. Each gets a different prescription.

If you remember one thingA past clot means anticoagulation; no clot means aspirin; a past pregnancy loss adds prophylactic heparin in the next pregnancy.

Who gets what

The antibody activates platelets, vessel lining and complement.In the placenta the injury is more inflammation than clot, which is why heparin and aspirin help less than expected in early losses. The history (clot or pregnancy) chooses the drug; the antibody profile decides how aggressive to be.

THE PRESCRIPTION BY PATIENT (Tektonidou 2019; Sammaritano 2020) OUTSIDE PREGNANCYDURING PREGNANCY Clot (thrombotic) venous or arterial,with persistent antibody warfarin, INR 2 to 3,long term for most avoid apixaban andrivaroxaban full-dose heparinplus low-dose aspirin switch before week 6;warfarin again after birth Pregnancy only loss or placental disease,never a clot low-dose aspirinafter weighingbleeding risk losses: aspirin plusprophylactic heparin placental disease: aspirin,heparin by individual risk Antibody only no clot, no pregnancyevent low-dose aspirinif the antibody profileis high risk low-dose aspirinfrom 12 to 16 weeks;no heparin (Sammaritano)

INR international normalized ratio, the warfarin test · high-risk profile a persistent lupus anticoagulant, double or triple positivity, or persistently high antibody levels · triple positive all three tests persistently positive · low-dose aspirin 75 to 100 mg a day (81 mg in the US) · prophylactic heparin a fixed low dose, such as enoxaparin 40 mg once daily · placental disease delivery before 34 weeks for severe preeclampsia or a failing placenta (Tektonidou 2019)

How long, and how hard.Provoked first venous clot: the usual duration, longer with a high-risk profile. Unprovoked venous clot or arterial clot: long term. After an arterial clot, INR 2 to 3, INR 3 to 4, or INR 2 to 3 plus aspirin (Tektonidou 2019).

Why warfarin and not apixaban or rivaroxaban.Rivaroxaban against warfarin in triple-positive patients was stopped early: 7 arterial clots (4 strokes, 3 heart attacks) versus none on warfarin (the TRAPS trial, Pengo 2018). Apixaban was stopped early for strokes too (ASTRO-APS, Woller 2022). The European rheumatology recommendations (EULAR) advise against rivaroxaban in triple positivity and against direct oral anticoagulants after arterial events; elsewhere only if warfarin is impossible (Tektonidou 2019).

The woman with one fetal death at 24 weeks is treated, but she is not "classified".The treatment guidelines were written on the 2006 definitions, which she meets (Miyakis 2006). Under the 2023 research criteria a single fetal death scores 1 clinical point (Barbhaiya 2023).

Pregnancy loss: what the trials showed

LIVE BIRTH WITH TREATMENT Antiphospholipid antibodies + losses heparin + aspirin vs aspirin (Hamulyák 2020) about 27% more live births 5 trials, 1295 women; low certainty, one trial dominates Inherited thrombophilia + 2 or more losses heparin vs standard care (ALIFE2) 72% vs 71%: no difference 326 women randomized (Quenby 2023) Unexplained recurrent miscarriage aspirin + heparin, aspirin, placebo (ALIFE) 54.5%, 50.8%, 57.0%: no benefit 364 women randomized (Kaandorp 2010)

Screening for factor V Leiden or the prothrombin gene after miscarriages does not lead to a useful prescription.The ALIFE2 authors advise against both the heparin and the screening in recurrent loss with inherited thrombophilia (Quenby 2023). The antiphospholipid antibodies are the thrombophilia worth testing, because they change the prescription.

Decide in clinic

1. Antiphospholipid syndrome with a past clot, now pregnant or planning?
yes
Switch to full-dose heparin before week 6Full-dose heparin plus low-dose aspirin for the pregnancy; warfarin again after delivery, compatible with breastfeeding. Never a direct oral anticoagulant in pregnancy or breastfeeding.
no clot
2. Past pregnancy loss or placental disease with persistent antibodies?
yes
Low-dose aspirin plus prophylactic heparinAspirin from early pregnancy; prophylactic heparin once the pregnancy is confirmed and for 6 weeks after delivery (Tektonidou 2019; 6 to 12 weeks in Sammaritano 2020). After early delivery for placental disease, aspirin alone is an option by individual risk.
still losing
3. Recurrent complications despite that?
yes
Escalate with the rheumatologist; the guidelines disagreeEuropean (EULAR): therapeutic-dose heparin, hydroxychloroquine, or low-dose prednisolone in the first trimester (Tektonidou 2019). American (ACR): add hydroxychloroquine; against raising heparin to therapeutic dose, against intravenous immunoglobulin and against prednisone (Sammaritano 2020). In the US, hydroxychloroquine is the usual next step.
separately
4. Antibodies negative, or only factor V Leiden or the prothrombin gene?
yes
No heparin for the lossesHeparin is for women with a clot history or other thrombotic risk, not to prevent miscarriage (Quenby 2023; Kaandorp 2010).

Small-vessel clots in three or more organs within a week: catastrophic antiphospholipid syndrome.Triggers: infection, surgery, stopping or under-dosing anticoagulation, and pregnancy or the weeks after delivery, where it mimics HELLP syndrome and thrombotic microangiopathy (Asherson 2003). Heparin, glucocorticoids, and plasma exchange or intravenous immunoglobulin; this is an intensive care admission (Tektonidou 2019).

Sources

Retrieved from PubMed, read on Oct 23, 2026.

  1. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019. doi:10.1136/annrheumdis-2019-215213
  2. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020. doi:10.1002/art.41191
  3. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018. doi:10.1182/blood-2018-04-848333
  4. Woller SC, Stevens SM, Kaplan D, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 2022. doi:10.1182/bloodadvances.2021005808
  5. Hamulyák EN, Scheres LJ, Marijnen MC, et al. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev 2020. doi:10.1002/14651858.CD012852.pub2
  6. Quenby S, Booth K, Hiller L, et al. Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial. Lancet 2023. doi:10.1016/S0140-6736(23)00693-1
  7. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010. doi:10.1056/NEJMoa1000641
  8. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006. doi:10.1111/j.1538-7836.2006.01753.x
  9. Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 2023. doi:10.1002/art.42624
  10. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003. doi:10.1191/0961203303lu394oa